Company intelligence / Profile preview

Arrien Pharmaceuticals LLC

Ansonia, Connecticut, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Phase 1

Overview

As of May 2025, Arrien has multiple programs in development, with ARN-4079 (ITK x JAK3 inhibitor) for Alopecia Areata in Phase 1, ARN-0953 (hMELK inhibitor) for Hematologic Neoplasms in Early Phase 1, and two preclinical candidates. Previously, the company initiated Phase 1 trials for ARN-6039 for multiple sclerosis in 2016, and developed GRN-300 (SIK2/SIK3 inhibitor) for ovarian cancer which was acquired by Greenfire Bio in 2020.

Therapeutic areas: PulmonologyOncologyImmunologyDermatologyHematologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

arn-6039

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Arrien Pharmaceuticals LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrien Pharmaceuticals LLC.

Explore the full profile